Today, pharamaceutical company Fulcrum Therapeutics announced high level results from its phase 3 clinical trial of the drug losmapimod – called the REACH study. The company reported that the drug failed to show improvements in several of the tests carried out in the trial over a 48-week period.
Disappointing results from phase 3 FSHD clinical trial
12 September 2024
We’re sad to inform you that because of these disappointing results the company is suspending further development of the drug.
The REACH Phase 3 clinical trial was a global study that aimed to test if losmapimod was safe and effective for use in people living with facioscapulohumeral muscular dystrophy (FSHD). While there were no concerns about its safety, no improvement was observed in participants who received losmapimod compared to those who received a control drug (placebo).
The trial enrolled 260 participants across the world, including the UK. If you or your family member has been involved in the study, we recommend you contact the study site for further information.
We know this comes as a huge disappointment to the FSHD community, and if you’re in need of support, please call our helpline team on 0800 652 6352 or email info@musculardystrophyuk.org.
Read Fulcrum Therapeutics’ press release for more information.
STORIES LIKE THIS
Phase 3 clinical trial, the SAPPHIRE study, shows promising results in treating SMA
October 8, 2024
The Microscope Ball 2024 raises record amount
October 2, 2024
Jon Richardson reveals star-studded line-up for charity comedy night in Aylesbury
September 30, 2024